| 47.55 0.03 (0.06%) | 08-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 55.94 | 1-year : | 65.34 |
| Resists | First : | 47.9 | Second : | 55.94 |
| Pivot price | 47.45  |
|||
| Supports | First : | 47.1 |
Second : | 46.61 |
| MAs | MA(5) : | 47.54 | MA(20) : | 47.32 |
| MA(100) : | 38.58 |
MA(250) : | 32.71 |
|
| MACD | MACD : | 0.6  |
Signal : | 0.8 |
| %K %D | K(14,3) : | 64.9 |
D(3) : | 65.9 |
| RSI | RSI(14): 77.5 | |||
| 52-week | High : | 47.9 | Low : | 15.07 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DICE ] has closed below upper band by 35.0%. Bollinger Bands are 91.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 47.66 - 47.9 | 47.9 - 48.09 |
| Low: | 46.88 - 47.21 | 47.21 - 47.48 |
| Close: | 47.1 - 47.59 | 47.59 - 47.98 |
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Tue, 08 Aug 2023
Lilly Completes Acquisition of DICE Therapeutics | Eli Lilly and Company - Investors | Eli Lilly and Company
Mon, 03 Jul 2023
How a Peninsula biotech turned its psoriasis drugs into a $2.4 billion acquisition - San Francisco Business Times - The Business Journals
Fri, 23 Jun 2023
Eli Lilly Announces $2.4B Acquisition of Immunology Company Dice Therapeutics - PharmaNewsIntel
Wed, 21 Jun 2023
Eli Lilly makes ambitious immunology play in $2.4bn DICE therapeutics acquisition - Pharmaceutical Technology
Tue, 20 Jun 2023
Eli Lilly To Acquire Small Company DICE Therapeutics Focused On Autoimmune Diseases For $2B - Yahoo Finance
Tue, 20 Jun 2023
Lilly bets on IL-17-focused Dice Therapeutics with $2.4B deal - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 105.8 (%) |
| Shares Short | 4,880 (K) |
| Shares Short P.Month | 8,110 (K) |
| EPS | -2.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.18 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -21.92 |
| PEG Ratio | 0.9 |
| Price to Book value | 3.99 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|